SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community discusses the launch of the $DOJE ETF, with some anticipating significant price movement. Talk centers around potential accumulation strategies and whether the ETF will trigger a major rally, although the launch may be delayed. There's also discussion around Dogecoin's long-term value and comparisons to other cryptocurrencies.

The project is a derivative of Fartcoin. The Fartcoin deployer has deployed this token because the President at Bone Fide Wealth tweeted about "A client just called and asked me if there’s going to be a Fartcoin ETF this year." Since the Elon narrative is has been running this one has come to existence. The token is following different narratives like Fartcoin, SPX500 and other big memes following the Trump narrative.

Elon Trump Fart

ETF500.X is trending as the community rallies, emphasizing its strength and long-term vision, particularly after the CEO departure. Discussions highlight the token as Solana's first ETF, with many proclaiming it as the best ETF ever. The community is focused on accumulation, anticipating a significant move.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

aTyr Pharma ($ATYR) is trending as traders anticipate Phase 3 data for its lead drug, efzofitimod, in mid-September, creating a high-stakes binary event. The community is buzzing with debate around the trial's design, potential outcomes, and the influence of figures like Martin Shkreli, with some expecting a short squeeze if results are positive. Bullish sentiment is fueled by recent analyst ratings and commercial hires, while bears point to past trial data and high implied volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is trending amid heated discussions around the political motivations behind a recent tragedy, sparking intense debate within the community.  Users are clashing over affiliations and broader cultural grievances, with some pointing fingers and others calling for unity. The conversation highlights the deep divisions and sensitivities surrounding the symbol and its association with political figures.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders discuss potential volatility catalysts, including upcoming economic data and geopolitical tensions. Community members are weighing the potential for a market correction against the effects of contango on the ETF. Some traders are using UVIX to hedge long positions or speculating on short-term price movements.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is trending as the stock experiences volatility amidst analyst upgrades and price target adjustments, leading to community debate on its near-term direction. Discussions revolve around recent price drops being potential profit-taking opportunities or possible manipulation, while others point to strong data center growth prospects and AI networking as long-term bullish factors. Community members are actively trading options and debating entry points, particularly around key technical levels.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE.X is trending as the community discusses its potential for growth and compares it to other meme coins like SHIB.X and DOGE.X. Some users are expressing frustration with price fluctuations, while others remain optimistic about long-term gains, with some linking its future to the 4chan community and the broader meme culture. The conversation also includes discussion around potential market manipulation and the importance of secure crypto storage.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recent $20 million investment agreement, sparking community discussion about its potential impact and whether it signals a true turning point or further dilution. Community members are actively trading the stock, anticipating significant price movement based on the low float and upcoming conference, with some looking for a short squeeze. The stock is also being compared to other high-flying low floaters.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amid discussions about its price action compared to other meme coins like Dogecoin, with some community members expressing frustration over its lack of upward momentum. Some are pointing to the potential for a breakout while others are calling it a scam. The community is also closely watching for any news regarding potential developments and market expansions.

Volatility Shares Trust - 2x Bitcoin Strategy ETF

Volatility Shares 2x Bitcoin Strategy ETF

BITX is trending as traders assess Bitcoin's potential near all-time highs and its impact on leveraged ETFs. Community discussions revolve around market volatility, technical analysis, and the broader implications of economic policies. Concerns about potential market corrections and the influence of external factors such as political events are also driving interest in BITX.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio (ANAB) delivered earnings and revenue surprises of +10.67% and +36.82%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AnaptysBio Inc.’s shares rose to a six-month high on Tuesday following the announcement of successful Phase 2b results from testing their experimental rheumatoid arthritis medication rosnilimab.The stock closed 7.6% higher at $23.52 on Tuesday, extending gains by another 5.1% to $24.71 in after-hours trading.A trial involving 424 patients proved that rosnilimab, a PD-1+ T cell depleter and agonist, delivered similar effectiveness to JAK inhibitors when administered&nbsp;monthly.&nbsp;Patients saw significant disease activity improvements through reductions in the Clinical Disease Activity Index (CDAI) and ACR70 response rates, which lasted for six months.The treatment-free period of up to two months showed sustained patient responses, which signals the possibility for longer dosing intervals.&nbsp;According to the company, no serious treatment-related adverse events appeared during the study, and the drug demonstrated superior tolerability compared to existing biologics and JAK inhibitors.On Stocktwits, retail sentiment was ‘bearish’ amid ‘extremely high’ message volume.One user&nbsp;suggested the stock was being "pumped" and speculated that a direct offering might follow.&nbsp;<stembedurl>https://stocktwits.com/Yukinvestor/message/616705356</stembedurl>Another user said they expected the updated data to disappoint and anticipated a potential offering.<stembedurl>https://stocktwits.com/Yukinvestor/message/616686959</stembedurl>The stock has risen 76.1% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an AnaptysBio logo seen displayed on a smartphone screen on a desk next to a Macbook in Athens, Greece on November 12, 2022. (Photo Illustration by Nikolas Kokovlis/NurPhoto via Getty Images)

AnaptysBio Stock Jumps On Promising Rheumatoid Arthritis Drug Readout; Retail Traders Brace For Potential Offering

The company reported successful mid-stage results for its rheumatoid arthritis drug rosnilimab, which matched the efficacy of JAK inhibitors with fewer side effects.

Equity

What’s the role of generative AI in drug discovery?

Investing.com -- Generative AI is emerging as a transformative long-term force in drug discovery, a field historically characterized by lengthy timelines, high costs, and low success rates.

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist Vanda Pharmaceuticals and Anaptys Announce...

Shares of AnaptysBio Inc. remained flat in premarket trading Thursday after plunging over 32% in the prior session, marking the stock’s steepest single-day loss since March 2021.&nbsp;The collapse followed the company’s announcement that it would halt further investment in its experimental therapy ANB032 after the drug failed to meet primary and secondary endpoints in a Phase 2b trial for moderate-to-severe atopic dermatitis, commonly known as eczema.Wednesday’s drop pushed AnaptysBio stock to its lowest closing level since December 2023, intensifying concerns among retail investors.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_12_at_5_59_31_PM_c4fa8def22.png" alt="Screenshot 2024-12-12 at 5.59.31 PM.png" width="1318" height="324"><figcaption>ANAB sentiment meter and message volume on Dec 12 premarket as of 7:30 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for AnaptysBio plunged into ‘extremely bearish’ levels before the bell on Thursday, following a 20% jump in message volume in the previous session.<stembedurl>https://stocktwits.com/SurdifiedStocks/message/596025184</stembedurl><stembedurl>https://stocktwits.com/Blossom_Tradez/message/595998006</stembedurl>AnaptysBio stated that it would redirect its resources and capital toward other investigational autoimmune therapies.&nbsp;The company plans to report top-line Phase 2b data for rosnilimab in rheumatoid arthritis by February 2025 and Phase 2 data for ulcerative colitis in the first quarter of 2026.Wall Street analysts quickly adjusted their outlooks. H.C. Wainwright downgraded the stock to ‘Neutral’ from ‘Buy,’ slashing its price target from $52 to $19.&nbsp;The brokerage expressed disappointment but not surprise, citing the high-risk nature of the ANB032 program. It also lowered its probability of success estimates for rosnilimab in rheumatoid arthritis from 50% to 40% and for ulcerative colitis from 40% to 30%.Wells Fargo analyst Derek Archila lowered the firm’s price target for AnaptysBio to $40 from $56 but maintained an ‘Overweight’ rating.&nbsp;Archila noted that while the Phase 2b trial’s failure aligns with their bear-case scenario, the shares’ current valuation offers a favorable risk/reward profile ahead of upcoming Phase 2 data releases.AnaptysBio's stock has lost over 28% year-to-date as of Wednesday’s close, with the latest developments adding further pressure on its stock performance and investor confidence.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an AnaptysBio logo is displayed on a smartphone screen with a computer wallpaper in the background in Athens, Greece on May 5, 2021. (Photo by Nikolas Kokovlis/NurPhoto via Getty Images)

AnaptysBio Stock Under Pressure After Scrapping Eczema Drug Program: Retail Is Devastated

Wednesday’s drop pushed AnaptysBio stock to its lowest closing level since December 2023, intensifying concerns among retail investors.

A Glimpse Into The Expert Outlook On AnaptysBio Through 6 Analysts

Latest Ratings for ANAB
 DateFirmActionFromTo Mar 2022HC Wainwright & Co.MaintainsBuy Jun 2021HC Wainwright & Co.Initiates Coverage OnBuy May 2021UBSInitiates Coverage OnNeutral
 View More...

What Analysts Are Saying About AnaptysBio Stock

AnaptysBio: Strong Buy Rating on Robust Equity Raise and Promising Clinical Pipeline

AnaptysBio (ANAB Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wa...

AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst

HC Wainwright initiated coverage on AnaptysBio with a Buy rating and a $55 price target. AnaptysBio focuses on immunology therapeutics with a promising pipeline.

 Latest Ratings for ANAB...

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$1.44	--	--	N/A
Q2 '25	-$1.55	-$1.34	13.59%	BEAT
Q1 '25	-$1.25	-$1.28	-2.15%	MISSED
Q4 '24	-$1.62	-$0.72	55.54%	BEAT
Q3 '24	-$1.65	-$1.14	30.78%	BEAT

ANAB
AnaptysBio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest ANAB News

ANAB AnaptysBio Inc